Lv11
40 积分 2021-09-06 加入
Data from Anlotinib plus TQB2450, a PD-L1 Antibody, in Patients with Advanced Alveolar Soft Part Sarcoma: A Single-Arm, Phase II Trial
8小时前
已完结
Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial
9小时前
已完结
Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial
2天前
已完结
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
2天前
已完结
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
4天前
已完结
Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer
1个月前
已完结
D3S-001 in advanced solid tumors with KRASG12C mutations: a phase 1 trial
3个月前
已完结
Mechanisms of primary resistance to immune checkpoint inhibitors in NSCLC
4个月前
已完结
The Role of Immunotherapy in Triple-Negative Breast Cancer (TNBC)
4个月前
已完结
Safety and Effectiveness of Immune Checkpoint Inhibitors in Older Patients with Cancer: A Systematic Review of 48 Real-World Studies
5个月前
已完结
皖公网安备34019202002308
